Premium
Dermasence refining gel modulates pathogenetic factors of rosacea in vitro
Author(s) -
Borelli C,
Becker B,
Thude S,
Fehrenbacher B,
Isermann D
Publication year - 2017
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12323
Subject(s) - rosacea , pathogenesis , in vitro , medicine , immunology , dermatology , chemistry , biochemistry , acne
Summary Background Over the counter cosmetics sold for local treatment of slight to moderate rosacea often state the claim of actively modulating rosacea pathogenesis. Factors involved in the pathogenesis of this common yet complex skin disorder include kallikrein‐related peptidase 5 ( KLK 5), LL ‐37, as well as protease‐activated receptor 2 ( PAR 2) and vascular endothelial growth factor ( VEGF ). Objective The objective was to prove the modulating effect of the cosmetic skin care agent Dermasence Refining Gel ( DRG ) on factors involved in rosacea pathogenesis. Methods We analyzed the effect of DRG on the expression of KLK 5, LL ‐37, PAR 2, and VEGF in an in vitro skin model of human reconstituted epidermis. Results The expression of CAMP ( LL ‐37 gene, fold change −4.19 [±0.11]), VEGFA (fold change −2.55 [±0.12]) and PAR 2 (−1.33 [±0.12]) was reduced, KLK 5 expression increased (fold change 2.06 (±0.08)) after 18 h of treatment with DRG in comparison to treatment with the matrix gel only. The reduction in CAMP expression was significant ( P <.01). The protein expression of all four inflammatory markers was markedly reduced after 18 hours of DRG treatment in comparison to baseline (0 hour), by measure of fluorescence intensity. Conclusion We show evidence explaining the anti‐inflammatory effect of Dermasence Refining Gel in rosacea pathogenesis in vitro. The adjunctive use of DRG in mild to moderate rosacea as a topical cosmetic seems medically reasonable.